Sign In
Buy LGVN
$0.80
-0.0197 (-2.40%)
At Close: Jun 22, 2026
Longeveron: A High-Quality Emerging Biotech Play
11:44am, Tuesday, 13'th Apr 2021
Stem cell research is an arm of biotechnology that has gained a lot of momentum over recent years. Many companies are focused on developing therapies using specialized cells from within the human body
LGVN Stock: Over 25% Increase Pre-Market Explanation
09:07am, Tuesday, 13'th Apr 2021
The stock price of Longeveron Inc. (Nasdaq: LGVN) increased by over 25% pre-market. This is why it happened.
SmallCapsDaily: Longeveron Inc. Emerges as a True Blue Bio-Tech Titan
08:00am, Monday, 12'th Apr 2021
New York, New York--(Newsfile Corp. - April 12, 2021) - Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic agi
LGVN Stock Price Increased 12.54%: Why It Happened
06:58pm, Tuesday, 30'th Mar 2021
The stock price of Longeveron Inc (NASDAQ: LGVN) increased by 12.54%. This is why it happened.
Longeveron's (LGVN) CEO Geoff Green on Q4 2020 Results - Earnings Call Transcript
12:43pm, Tuesday, 30'th Mar 2021
Longeveron's (LGVN) CEO Geoff Green on Q4 2020 Results - Earnings Call Transcript
Longeveron Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results
07:00am, Tuesday, 30'th Mar 2021
MIAMI, March 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
Longeveron Schedules 2020 Fiscal Year End Business Update Conference Call
09:00am, Friday, 26'th Mar 2021
MIAMI, March 26, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
Longeveron Inc. to Present at the Q1 Virtual Investor Summit on March 24
07:45am, Friday, 19'th Mar 2021
MIAMI, March 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chro
Longeveron Inc. Announces Partial Exercise of Over-Allotment Option in Initial Public Offering
04:30pm, Monday, 15'th Mar 2021
MIAMI, March 15, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) ("Longeveron" or the "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related
LGVN Stock Price Increased Over 73% Intraday: Why It Happened
09:56am, Thursday, 11'th Mar 2021
The stock price of Longeveron Inc. (NASDAQ: LGVN) has increased by over 73% during intraday trading as of this morning. This is why it happened.
Trial funded in part by a Maryland Stem Cell Research Fund TEDCO Grant Trial funded in part by a Maryland Stem Cell Research Fund TEDCO Grant
Longeveron Announces Successful Completion of Phase 2b Clinical Study of Lomecel-B Infusion to Treat Aging Frailty
08:30am, Wednesday, 03'rd Mar 2021
Trial funded in part by a National Institute on Aging Small Business Innovation Research (SBIR) Grant
Longeveron's Allogeneic Cell Therapy Completes Early-Stage Study In Congenital Heart Defect
01:44pm, Wednesday, 24'th Feb 2021
Longeveron Inc (NASDAQ: LGVN) completes Phase 1 study of Lomecel-B in Hypoplastic Left Heart Syndrome (HLHS). Full results from the study will be released in Q2 2021.
CEO of Longeveron Inc. to Present at the Intercontinental Summit on Aging & Gerontology
08:30am, Friday, 19'th Feb 2021
MIAMI, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and
